FDA
-
-
-
-
-
-
-
Rigel licenses VEPPANU breast cancer drug for $85 million upfront
-
-
-
-
-
-
-
Rigel Provides Business Update and 2026 Outlook
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Rigel Pharmaceuticals (RIGL)
-
-
-
-
-
-
-
Rigel Pharma (RIGL) Announces Settlement Agreement Resolving TAVALISSE Patent Litigation
-
-
-
-
-
-
-
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease
-
-
-
-
-
-
-
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
-
-
-
-
-
-
-
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
-
324,757 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

